Sequent Scientific reported a 15.6 percent jump in its revenues at Rs 265.2 crore versus Rs 229.5 crore reported for the same quarter last fiscal. The year on year EBITDA in Q2 was also up 88 percent at Rs 35.7 crore versus Rs 19 crore.
Margins jumped 13.4 percent versus 8.2 percent YoY and profit was up at Rs 13 crore versus loss of 4.34 crore YoY.
The US FDA recently approved Vizag plant.
Manish Gupta, CEO of Sequent Scientific in an interview to CNBC-TV18 shared the outlook for the company going forward and the some details of the second quarter performance.
He said the board has declared an interim dividend of 10 percent after a gap of six years, which reflects the confidence for the future.
He is confident of being on a positive growth track in terms of revenues and margins going forward.
SeQuent has emerged as an integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (API and formulation) and Human health (API).For the full interview, watch video